The Science
At the core of our innovation lies our expertise in engineering Vesicular Stomatitis Virus (VSV), a versatile and powerful platform for oncolytic virotherapy. VSV is uniquely suited for cancer treatment due to its natural ability to replicate selectively in cancer cells while sparing healthy ones.
OUR INNOVATION
One of our key innovations is the incorporation of suicide gene delivery into the VSV platform.
This cutting-edge technique allows for precision killing by introducing genes that trigger cancer cell death only in targeted areas, sparing healthy tissues. These synergistic strategies not only improve treatment efficacy but also reduce side effects, offering a comprehensive and patient-friendly approach to combating cancer.
Tumor-Specific Targeting
Our research is dedicated to enhancing the tumor specificity of Vesicular Stomatitis Virus (VSV) through cutting-edge innovations in “oncotropism”—the virus’s ability to selectively target and replicate in cancer cells. By engineering glycoprotein modifications and incorporating mechanisms to recognize tumor-specific antigens, we ensure precise targeting of cancerous tissues while leaving healthy cells unharmed. These advancements make our platform highly effective and safe, maximizing therapeutic outcomes for diverse cancer types.
Synergistic Therapies
Our approach leverages the power of Vesicular Stomatitis Virus (VSV) in combination with existing cancer therapies to achieve superior outcomes. By integrating VSV with chemotherapy, we amplify the virus’s tumor-killing effects while minimizing drug resistance. Additionally, when paired with immunotherapy, VSV enhances immune system activation, turning the tumor microenvironment into a battlefield against cancer cells.
Why VSV?
Nature’s Safest, Most Adaptable Virus, Engineered to Fight Cancer in Ways Others Can’t
Non-pathogenic to humans
VSV naturally causes mild or no symptoms in humans, making it an ideal candidate for therapeutic use. Unlike other viruses, it has evolved to coexist with human hosts without causing significant disease, providing an inherent safety advantage for medical applications.
Highly tunable via genetic engineering
The simple structure of VSV’s genome allows for precise modifications to enhance its cancer-fighting abilities. Our scientists can engineer specific genes into VSV that improve its targeting accuracy and therapeutic effectiveness, similar to reprogramming a smart missile to better reach its target.
Effective in hypoxic environments
Many tumors create oxygen-poor environments that resist traditional treatments. VSV thrives in these challenging conditions, continuing to attack cancer cells even in areas where other therapies fail. This unique ability allows it to destroy cancer cells in traditionally hard-to-treat tumor regions.
A STRONG AND VERSATILE PLATFORM
Kure leverages VSV’s adaptability as a customizable tool
1.
Precision Engineering
VSV’s genome to enhance its ability to target and destroy cancer cells while ensuring safety for normal tissues.
2.
Enhanced Lytic Potential
By optimizing VSV’s replication machinery, we amplify its ability to cause rapid and effective tumor destruction.
3.
Immune Activation
VSV is engineered to stimulate the patient’s immune system, turning it into an active participant in fighting cancer.
4.
Versatility across cancer types
Our advancements allow VSV to be tailored for a wide range of cancers, making it a universal and scalable therapeutic option.